Axsome Therapeutics Inc (NASDAQ: AXSM) on Friday, soared 6.70% from the previous trading day, before settling in for the closing price of $129.10. Within the past 52 weeks, AXSM’s price has moved between $64.11 and $134.18.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 96.67% over the last five years. The company achieved an average annual earnings per share of 59.55%. With a float of $40.02 million, this company’s outstanding shares have now reached $48.67 million.
The firm has a total of 683 workers. Let’s measure their productivity. In terms of profitability, gross margin is 90.89%, operating margin of -73.11%, and the pretax margin is -74.45%.
Axsome Therapeutics Inc (AXSM) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Axsome Therapeutics Inc is 17.94%, while institutional ownership is 77.77%. The most recent insider transaction that took place on Feb 13 ’25, was worth 1,558,320. In this transaction Chief Financial Officer of this company sold 12,000 shares at a rate of $129.86, taking the stock ownership to the 42,187 shares. Before that another transaction happened on Feb 14 ’25, when Company’s Chief Financial Officer sold 3,000 for $131.07, making the entire transaction worth $393,210. This insider now owns 42,187 shares in total.
Axsome Therapeutics Inc (AXSM) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.09 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 59.55% per share during the next fiscal year.
Axsome Therapeutics Inc (NASDAQ: AXSM) Trading Performance Indicators
Axsome Therapeutics Inc (AXSM) is currently performing well based on its current performance indicators. A quick ratio of 2.04 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.42.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -6.00, a number that is poised to hit -1.28 in the next quarter and is forecasted to reach 3.04 in one year’s time.
Technical Analysis of Axsome Therapeutics Inc (AXSM)
Analysing the last 5-days average volume posted by the [Axsome Therapeutics Inc, AXSM], we can find that recorded value of 1.15 million was better than the volume posted last year of 1.1 million. As of the previous 9 days, the stock’s Stochastic %D was 83.63%. Additionally, its Average True Range was 6.01.
During the past 100 days, Axsome Therapeutics Inc’s (AXSM) raw stochastic average was set at 97.83%, which indicates a significant increase from 96.07% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 85.31% in the past 14 days, which was higher than the 55.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $101.36, while its 200-day Moving Average is $89.77. Now, the first resistance to watch is $141.79. This is followed by the second major resistance level at $145.83. The third major resistance level sits at $152.54. If the price goes on to break the first support level at $131.05, it is likely to go to the next support level at $124.34. Now, if the price goes above the second support level, the third support stands at $120.30.
Axsome Therapeutics Inc (NASDAQ: AXSM) Key Stats
Market capitalization of the company is 6.72 billion based on 48,765K outstanding shares. Right now, sales total 270,600 K and income totals -239,240 K. The company made 104,760 K in profit during its latest quarter, and -64,600 K in sales during its previous quarter.
